MiR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation

Cancer Research

Volumn 73, Issue 2, 2013, Pages 756-766

  Cai, Junchao ^a,b   Wu, Jueheng ^a,b   Zhang, Huizhong ^c   Fang, Lishan ^a,b   Huang, Yongbo ^a,b   Yang, Yi ^a,b   Zhu, Xun ^a,b   Li, Rong ^a,b   Li, Mengfeng ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 6; MICRORNA; MICRORNA 186; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; EPITHELIUM CELL; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RNA INTERFERENCE;

ADENOCARCINOMA; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN D2; CYCLIN-DEPENDENT KINASE 6; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; RNA, SMALL INTERFERING;

EID: 84872530278     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2651     Document Type: Article

References (39)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008:GLOBOCAN2008. Int J Cancer 2010;127: 2893-917.
2. Jemal A, Bray F, CenterMM,Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61: 69-90.
3. Buyukcelik A, Yalcin B, Utkan G. Multidisciplinary management of lung cancer. N Engl J Med 2004;350: 2008-10.
4. Pallis AG, Fennell DA, Szutowicz E, Leighl NB, Greillier L, Dziadziuszko R. Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer. Br J Cancer 2011;105: 1-8.
5. Lovly CM, Carbone DP. Lung cancer in 2010: one size does not fit all. Nat Rev Clin Oncol 2011;8: 68-70.
6. Moran C. Importance of molecular features of non-small cell lung cancer for choice of treatment. Am J Pathol 2011;178: 1940-8.
7. Eymin B, Gazzeri S. Role of cell cycle regulators in lung carcinogenesis. Cell Adhes Migr 2010;4: 114-23.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
9. Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 2007;55: 1-14.
10. Schauer IE, Siriwardana S, Langan TA, Sclafani RA. Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci U S A 1994;91: 7827-31.
11. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81: 323-30.
12. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999;98: 859-69.
13. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 2003;4: 181-9.
14. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13: 1501-12.
15. Caputi M, Russo G, Esposito V, Mancini A, Giordano A. Role of cellcycle regulators in lung cancer. J Cell Physiol 2005;205: 319-27.
16. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med 2009;60: 167-79.
17. Stahlhut Espinosa CE, Slack FJ. The role of microRNAs in cancer. Yale J Biol Med 2006;79: 131-40.
18. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9: 189-98.
19. Dalmay T, Edwards DR. MicroRNAs and the hallmarks of cancer. Oncogene 2006;25: 6170-5.
20. Tsai MF, Wang CC, Chang GC, Chen CY, Chen HY, Cheng CL, et al. A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma. J Natl Cancer Inst 2006;98: 825-38.
21. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 2000;60: 4894-906.
22. Ibrahim L, Dominguez M, Yacoub M. Primary human adult lung epithelial cells in vitro: response to interferon-gamma and cytomegalovirus. Immunology 1993;79: 119-24.
23. Li J, Zhang N, Song LB, Liao WT, Jiang LL, Gong LY, et al. Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin Cancer Res 2008;14: 3319-26.
24. Tan LP, Seinen E, Duns G, de Jong D, Sibon OC, Poppema S, et al. A high throughput experimental approach to identify miRNA targets in human cells. Nucleic Acids Res 2009;37:e137.
25. Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, et al. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 2008;28: 1213-23.
26. Chen CC, Hwang JJ, Ting G, Tseng YL, Wang SJ, Whang-Peng J. Monitoring and quantitative assessment of tumor burden using in vivo bioluminescence imaging. Nucl Instrum Methods A 2007;571: 437-41.
27. Zhang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q, et al. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg 2009;33: 698-709.
28. Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L, et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 2010;70: 367-77.
29. Lv SQ, KimYH, Giulio F, Shalaby T, Nobusawa S, Yang H, et al. Genetic alterations in microRNAs in medulloblastomas. Brain Pathol 2012;22: 230-9.
30. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011;11: 558-72.
31. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994;369: 669-71.
32. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001;411: 1017-21.
33. Matushansky I, Radparvar F, Skoultchi AI. CDK6 blocks differentiation: coupling cell proliferation to the block to differentiation in leukemic cells. Oncogene 2003;22: 4143-9.
34. Fujimoto T, Anderson K, Jacobsen SE, Nishikawa SI, Nerlov C. Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/EBPalpha interaction. EMBO J 2007;26: 2361-70.
35. Igarashi K, Masaki T, Shiratori Y, Rengifo W, Nagata T, Hara K, et al. Activation of cyclin D1-related kinase in human lung adenocarcinoma. Br J Cancer 1999;81: 705-11.
36. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1: 222-31.
37. Galimberti F, Thompson SL, Liu X, Li H, Memoli V, Green SR, et al. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clin Cancer Res 2009;16: 109-20.
38. Malumbres M, Sotillo R, Santamaria D, Galan J, Cerezo A, Ortega S, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004;118: 493-504.
39. Kozar K, Ciemerych MA, Rebel VI, Shigematsu H, Zagozdzon A, Sicinska E, et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 2004;118: 477-91.